Show simple item record

dc.contributor.authorFavié, Laurent Ma
dc.contributor.authorMurk, Jean-Luc
dc.contributor.authorMeijer, Adam
dc.contributor.authorNijstad, A Laura
dc.contributor.authorvan Maarseveen, Erik M
dc.contributor.authorSikma, Maaike A
dc.date.accessioned2018-02-08T13:25:24Z
dc.date.available2018-02-08T13:25:24Z
dc.date.issued2017-11-29
dc.identifier.citationPharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza. 2017 Antivir. Ther. (Lond.)en
dc.identifier.issn2040-2058
dc.identifier.pmid29185991
dc.identifier.doi10.3851/IMP3210
dc.identifier.urihttp://hdl.handle.net/10029/621381
dc.description.abstractFavipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous hemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.
dc.language.isoenen
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.titlePharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.en
dc.typeArticleen
dc.identifier.journalAntivir Ther 2018; 23(5):457-61en
html.description.abstractFavipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous hemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.


This item appears in the following Collection(s)

Show simple item record